Goldman Sachs analyst David Roman raised the firm’s price target on Bausch + Lomb (BLCO) to $19 from $17 and keeps a Neutral rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Evercore ISI upgrades four, downgrades six in MedTech and Tools
- Bausch + Lomb downgraded to In Line from Outperform at Evercore ISI
- Bausch + Lomb refinances term loans, extends maturities
- Bausch + Lomb to Present at 44th Annual J.P. Morgan Healthcare Conference
- Bausch + Lomb Adds New Directors to Board